Characteristics | Total(n = 260) | EBV-positive(n = 16) | EBV-negative(n = 244) | P value | |||
---|---|---|---|---|---|---|---|
No. | % | No. | % | No. | % | ||
Sex(male/female) | 260(157/103) | 16(11/5) | 244(146/98) | 0.492 | |||
Age(y) median(range) | 55(15–85) | 58.5(38–84) | 55(15–85) | ||||
Subgroup | |||||||
GCB | 66/176 | 37.5 | 5/15 | 33.3 | 61/161 | 37.9 | 0.727 |
non-GCB | 110/176 | 63.5 | 10/15 | 66.7 | 100/161 | 62.1 | |
Initial Chemotherapy | |||||||
R-CHOP | 162/260 | 62.3 | 8/16 | 50.0 | 154/244 | 63.1 | 0.294 |
CHOP | 69/260 | 26.5 | 4/16 | 25.0 | 65/244 | 26.6 | 0.886 |
other | 18/260 | 6.9 | 1/16 | 6.3 | 17/244 | 7.0 | 0.913 |
no treatment | 11/260 | 4.2 | 3/16 | 18.8 | 8/244 | 3.3 | 0.003 |
Therapeutic response | |||||||
CR | 108/228 | 47.6 | 2/12 | 16.7 | 106/216 | 49.1 | 0.029 |
PR | 45/228 | 19.8 | 4/12 | 33.3 | 41/216 | 19.0 | 0.224 |
SD | 4/228 | 1.8 | 0/12 | 0.0 | 4/216 | 1.9 | 0.634 |
PD | 71/228 | 31.3 | 6/12 | 50.0 | 65/216 | 30.1 | 0.147 |
Clinical stage | |||||||
I | 32/251 | 12.7 | 1/15 | 6.7 | 31/236 | 13.1 | 0.466 |
II | 39/251 | 15.5 | 1/15 | 6.7 | 38/236 | 16.1 | 0.328 |
III | 58/251 | 23.1 | 0/15 | 0 | 58/236 | 24.6 | 0.029 |
IV | 122/251 | 48.6 | 13/15 | 86.7 | 109/236 | 46.2 | 0.002 |
B symptoms present | 95/260 | 36.5 | 10/16 | 62.5 | 85/244 | 34.8 | 0.026 |